SCHEMBL25008186

SCHEMBL25008186

O=C1CCCCN1CCCNc1nc(Cl)ncc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 6/20 0.45
HSD17B10 Q99714 4/20 0.45
LMNA P02545 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
ULK1 O75385 1/20 0.44
ULK2 Q8IYT8 1/20 0.44
PGK1 P00558 1/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
GFER P55789 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HPGD P15428 3/20 0.41
STK17A Q9UEE5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27087788 0.97 SMN1; SMN2 (0.51) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL29989339 0.97 SMN1; SMN2 (0.51) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22664753 0.87 SMN1; SMN2 (0.48) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL25008208 0.87 ULK1 (0.58) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22664750 0.86 SMN1; SMN2 (0.47) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL25008387 0.86 ULK1 (0.44) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22648409 0.85 ALDH1A1 (0.51) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22648370 0.85 SMN1; SMN2 (0.48) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22635407 0.84 ALDH1A1 (0.50) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22672870 0.84 SMN1; SMN2 (0.51) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed
EP-4320121-A2 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF LifeArc (GB) 2024-02-14 EP disclosed
CN-117545751-A 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use 生命爱科 2024-02-09 CN disclosed
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-09 US disclosed
WO-2022214869-A2 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 SMN1; SMN2 3477/4885HTT 927/4885ALDH1A1 2271/4885
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 SMN1; SMN2 2564/4885HTT 1394/4885ALDH1A1 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.